Phase II clinical trial of peptide vaccination with HLA-A2402-restricted KIF20A and VEGFR1 epitope peptides with gemcitabine chemotherapy in patients with unresectable advanced pancreatic cancer

Phase II clinical trial of peptide vaccination with HLA-A2402-restricted KIF20A and VEGFR1 epitope peptides with gemcitabine chemotherapy in patients with unresectable advanced pancreatic cancer - Phase II clinical trial of peptide vaccination with chemotherapy in patients with unresectable advanced pancreatic cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004641

Enrollment

Registered

2010-12-01

Start date

2010-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

Gemcitabine is administered at a dose of 1000 mg/m2 on days 1, 8, and 15 in a 28-day cycle. KIF20A and VEGFR1 peptides are subcutaneously injected weekly at each doses of 2 mg/body in patients with HL

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who have unresectable advanced pancreatic cancer before undergoing chemotherapy or vaccination. 2. Performance status (ECOG) of the patients are 0-2. 3. more than 20, less than 80 years of age. 4. The presence or absence of measurable or evaluable lesions by RECIST was not taken into account. 5. Patients who have undergone operation, and recovered the influence by surgery. Or two weeks or more have passed since pre-medical treatment. 6. Patients who can expect the survival of three months or more. 7. WBC count more than 3500/mm3, less than 10000/mm3. Plt count more than 100000/mm3. AST and ALT less than 150IU/L. T-Bil less than 2.0mg/dl. Creatinine less than 1.5mg/dl. 8. All patients gave written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients have uncontrollable associated cancer. 2. Patients have uncontrollable severe infectional diseases. 3. Patients have severe trauma. 4. Patients who are treated with steroid or immunotherapy during clinical trial. 5. Pregnancy or lactation. 6. Patients who have non-recovered injury. 7. Patients judged inappropriated by doctors.

Design outcomes

Primary

Measure	Time frame
overall survival	—

Countries

Japan

Contacts

Public ContactJunko Kato

Juntendo University School of Medicine Department of Gastroenterology

jun-kato@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026